Michael Risbano

Pathogenic Mechanism and Therapeutic Approaches for Exercise Intolerance in Post-Acute Sequelae of COVID-19

National Heart, Lung, and Blood Institute · R01

PI · $1.3M · University of Pittsburgh at Pittsburgh

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

Principal investigator · Not yet recruiting · Phase 1, Phase 2

Chan, Stephen, MD, PhD

miRNA and Myokines in Patients With PAH

Principal investigator · Withdrawn

University of Pittsburgh

Metformin for Pulmonary Hypertension HFpEF

Principal investigator · Completed · Phase 2

University of California, San Francisco

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Principal investigator · Completed · Phase 2

University of Pittsburgh